May 14 |
Legend Biotech's Carvykti Faces Stiff Challenges Despite Advances
|
May 14 |
Legend Biotech Corp (LEGN) Q1 2024 Earnings Call Transcript Highlights: Soaring CARVYKTI Sales ...
|
May 14 |
Q1 2024 Legend Biotech Corp Earnings Call
|
May 13 |
Legend Biotech Corporation 2024 Q1 - Results - Earnings Call Presentation
|
May 13 |
Legend Biotech Corporation (LEGN) Q1 2024 Earnings Call Transcript
|
May 13 |
Legend Biotech GAAP EPS of -$0.16 beats by $0.02, revenue of $93.99M misses by $47.37M
|
May 13 |
Legend Biotech Reports First Quarter 2024 Results and Recent Highlights
|
May 10 |
Legend Biotech Q1 2024 Earnings Preview
|
Apr 22 |
CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma
|
Apr 17 |
Scotiabank upgrades Legend Biotech to sector outperform
|